Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,744 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Clear all
Recruiting No phase listed Observational

Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.

NCT07845942
View directory record Official record
Conditions
Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis Associated Lung Disease
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 4 Interventional

Vasopressin for Septic Shock Pragmatic Trial

NCT06217562
View directory record Official record
Conditions
Septic Shock
Interventions
Vasopressin, Recommendation to use a lower initiation threshold for vasopressin, Recommendation to use a higher initiation threshold for vasopressin
Drug · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
3,959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Burley, Idaho • American Fork, Utah • Cedar City, Utah + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 4 Interventional

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

NCT03098823
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Erythematosus, Fatigue
Interventions
RAYOS, Prednisone
Drug
Lead sponsor
Ampel BioSolutions, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
21
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 28, 2026, 5:41 AM EDT
Terminated No phase listed Observational

Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator

NCT06426407
View directory record Official record
Conditions
Shock, Septic
Interventions
Vasopressin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Preventive Approach to Congenital Heart Block With Hydroxychloroquine

NCT01379573
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
Interventions
Hydroxychloroquine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 28, 2026, 5:41 AM EDT
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

NCT00089141
View directory record Official record
Conditions
Cancer
Interventions
mycophenolate mofetil, placebo
Drug
Lead sponsor
Martin, Paul
Other
Eligibility
4 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Not applicable Interventional

Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation

NCT00372502
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Modified EGDT, Standard EGDT
Procedure
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • Camden, New Jersey • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Oct 28, 2026, 5:41 AM EDT
Completed No phase listed Observational

Systemic Reactions to Allergen Immunotherapy Amd Skin Testing

NCT00594802
View directory record Official record
Conditions
SYSTEMIC REACTION
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 28, 2026, 5:41 AM EDT
Completed No phase listed Observational

Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus

NCT00582465
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years to 22 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 28, 2026, 5:41 AM EDT
Completed No phase listed Observational

ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)

NCT05347992
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 28, 2026, 5:41 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

INB03 for the Treatment of Pulmonary Complications From COVID-19

NCT04370236
View directory record Official record
Conditions
COVID-19
Interventions
INB03, Placebo
Drug
Lead sponsor
Inmune Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Impact of Overnight Active Temperature Regulation on the Gut Microbiome, Inflammation, and Circadian Rhythm.

NCT07848594
View directory record Official record
Conditions
Poor Sleep Quality, Gut Microbiome, Gut Health, Inflammation, Circadian Rhythm, Circadian Clocks, Gut Microbiota, Women's Health, Gut-Brain Axis, Blood Pressure, Systemic Inflammatory Response
Interventions
Overnight Active Temperature Regulation: Eight Sleep Pod System
Device
Lead sponsor
Eight Sleep Inc.
Industry
Eligibility
45 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Newton Center, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Limited Versus Extended Trophic Feeding (LET-FEED) Trial

NCT06893939
View directory record Official record
Conditions
Sepsis, Length of Stay, Mortality, Neurodevelopmental Delay
Interventions
Limited Trophic Feeds (1 day of trophic feeds), Extended Trophic Feeds (3 days of trophics)
Other
Lead sponsor
University of Washington
Other
Eligibility
0 Years to 2 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
6
States / cities
Birmingham, Alabama • Tampa, Florida • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Active, not recruiting Not applicable Interventional

Living Healthy for Moms RCT

NCT06666400
View directory record Official record
Conditions
Postpartum Depression (PPD), Cardiac Event
Interventions
LHMoms Intervention, No intervention
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Brooklyn, New York • Jamaica, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed No phase listed Observational

Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest

NCT01944605
View directory record Official record
Conditions
Cardiac Arrest, Reperfusion Injury
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

NCT00398619
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
INCB13739
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Beverly Hills, California • Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Oct 28, 2026, 5:41 AM EDT
Not yet recruiting Phase 4 Interventional

IO Vancomycin Administration in TKA

NCT07633418
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Intraosseous Vamcomycin Administration
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed No phase listed Observational

SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay

NCT02730468
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 28, 2026, 5:41 AM EDT
Terminated Phase 1 Interventional Results available

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

NCT02981082
View directory record Official record
Conditions
Systemic Sclerosis, Pulmonary; Hypertension
Interventions
Dimethyl Fumarate (DMF), Placebo Oral Tablet
Drug
Lead sponsor
Robert Lafyatis
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 28, 2026, 5:41 AM EDT
Recruiting Phase 1 Interventional

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

NCT06613360
View directory record Official record
Conditions
SLE, SLE (Systemic Lupus)
Interventions
CLN-978
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Avondale, Arizona • Tucson, Arizona • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Not applicable Interventional

Project 4B: Lower Extremity Strength Training in ICU Patients

NCT02467023
View directory record Official record
Conditions
Sepsis
Interventions
Muscle stimulation with Niveus medical stimulator, measurement of maximal isometric twitch strength, Muscle Biopsy, Muscle Biopsy Medication: Lidocaine, Muscle Biopsy Medication: Versed, Muscle Biopsy Medication: Fentanyl, Blood and Urine Sampling, ineffective muscle stimulation
Device · Procedure · Drug + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 28, 2026, 5:41 AM EDT
Not yet recruiting Not applicable Interventional

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit

NCT07811180
View directory record Official record
Conditions
Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU), Sepsis
Interventions
13C6-Glucose
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

NCT01972568
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
30
States / cities
Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 28, 2026, 5:41 AM EDT